Liver injury due to prescription and non-prescription medication is medical, scientific, and public health problem of increasing frequency and importance in United States. Drug-induced liver injury (DILI) is the most common reason the Food and Drug Administration (FDA) would choose not to approve a new drug or withdraw a drug from the market. However, drug-induced liver injuries are often under-reported and difficult to detect/diagnose. This study seeks to learn more about these drug-induced liver injuries and develop better ways to detect, define, and study drug-induced liver injuries. The study will be looking at new cases of drug-induced liver injury, as well as gathering data on previous drug-induced liver injury (up to January 1, 1994).
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Paul Watkins
UNC Eshelman School of Pharmacy-Division of Pharmacotherapy and Experimental Therapeutics
Clinical or Medical
Observational
Injury/Injury Prevention
Kidneys and Liver
23-3281